p53 gene therapy - Shenzhen SiBiono GeneTech
Alternative Names: Gendicine; p53 gene therapy - SiBiono; rAD-p53 - Shenzhen SiBiono GenTech; Recombinant Ad-p53 anti-cancer injection - SibionoLatest Information Update: 28 Oct 2023
Price :
$50 *
At a glance
- Originator Shenzhen SiBiono GeneTech
- Class Antineoplastics; Gene therapies
- Mechanism of Action Apoptosis stimulants; Gene transference; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Head and neck cancer
- Phase II Liver cancer
- No development reported Urogenital cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Urogenital-cancer in China
- 25 Sep 2019 Preclinical trials in Urogenital cancer in China (unspecified route)
- 25 Sep 2019 Preclinical pharmacodynamics data in Urogenital cancer presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2019)